Full Press Release Details
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Updated - Gabriele Cerrone, Chairman
of Tiziana Life Sciences to give interview on
Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021
NEW YORK and LONDON - 29 March 2021 - Tiziana
Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation,
and infectious diseases, clarifies that its Chairman and Founder, Gabriele Cerrone, will be giving an interview on Bloomberg Television
on Tuesday 30 March 2021 at 1.50 p.m. US Eastern Standard Time (6.50 p.m. London) as part of the Bloomberg Markets Show.
This is an amendment to the previous time
and date communicated.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc (TLSA)
Gabriele Cerrone, Chairman, and founder
U.S. Investor Relations Contact:
RedChip Companies, Inc.
1-800 RED-CHIP (733-2447)